Business
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (T...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (\"NurExone\" or the \"Company\"), a biotechnology company developing exosome-based therapies for central nervous system injuries, today announced that Dr. Lior Shaltiel, Chief Executive Officer, will participate in the upcoming Water Tower Research (\"WTR\") Insights Conference taking place on Tuesday, April 14, 2026, at 11:50 a.m. ET.The discussion is expected to cover NurExone's exosome-based therapeutic platform, recent corporate developments, and strategic priorities.The WTR Insights Conference is a virtual event designed for investors seeking direct access to company management teams and differentiated insights across innovative businesses.Investors may register for the event here.About WTRModernizing Investor Engagement Through Research-Driven Communications. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor engagement platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is open for everyone to access and distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients' businesses, industries, and the investment opportunities they present.About NurExoneNurExone is a TSX Venture Exchange (\"TSXV\"), OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the roadm...